Strengths

Negative cash conversion cycle suggests working-capital efficiency, but peers with commercialized products typically sustain positive returns rather than ABVC’s deeply negative ROIC.

Low leverage can preserve optionality, yet it is a weaker structural advantage than peers with stronger liquidity and operating cash generation.

Minimal debt reduces balance-sheet pressure, but it does not offset the absence of durable profitability that more established biotech peers usually exhibit.

Weaknesses

TTM ROIC of -51.98% indicates capital destruction, leaving ABVC structurally behind peers that at least preserve invested capital through recurring earnings.

Current and quick ratios of 0.07 signal severe liquidity strain, which is materially weaker than peers with cash buffers to fund development and operations.

The absence of reported operating and gross margins implies limited commercial scale, whereas stronger peers typically show clearer margin visibility and operating leverage.

Negative net debt to EBITDA is not a strength here because EBITDA is effectively absent, so leverage metrics provide little support versus better-capitalized peers.

Opportunities

If ABVC converts pipeline assets into revenue, margin and return metrics could improve from a low base, but peers with approved products would still retain a structural lead.

A low debt burden could support financing flexibility, yet peers with stronger liquidity can usually raise capital on better terms and with less dilution.

Any improvement in working-capital discipline could extend runway, but it would mainly narrow a weakness rather than create a durable competitive advantage.

Threats

Persistent liquidity weakness raises going-concern and dilution risk, making ABVC more vulnerable than peers with stronger cash positions and operating self-funding.

Negative ROIC increases the risk that additional capital will destroy value, while more mature peers can reinvest at positive incremental returns.

Without visible margin generation, ABVC faces a higher probability of financing dependence than peers with diversified revenue and established commercial execution.

Overall Score

ABVC’s structural positioning versus peers is weak because severe liquidity constraints and deeply negative capital returns outweigh limited balance-sheet leverage and any working-capital efficiency.